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In 1973,CML wasfurther character ized as at ranslocation of chromosomes9a nd 22. 2 Subsequently,i t wasd etermined thatt he 9:22 translocationc oded fort he BCRABLt yrosinek inase. General cytotoxicc hemotherapyd rugs were used at firstuntil interferon ∂ (IFN∂ )w as proven superior to cytoreductivetherapyinrandomizedtrialsin1994. 3 Thenext phasei nd rugd evelopment targeted theB CR-ABL proteinw ith thei nhibitor imatinib. The drug wasi nitiallya pprovedb yt he U.S. Food andDrugAdministration in 2001 andthena pproved as front-line therapyf or chronicp hase (CP) CMLin2 003. With widespread clinicaluse,imatinibresistancewas reported andthe mutationsleading to resistance were subsequently identified.The second-generationk inasei nhibitors, whichh ad efficacya gainst most of thesem utations,e ntered clinicalt rialsb y2 005. This work hasc ontinueda nd newd rugs thatt argett he 1r emaining resistantBCR-ABL mutation,T315I,are nowthe subject of ongoingclinicaltrials.
The currentt reatment goalsf or thep atient with CMLa re to maintain remissiona nd preventp rogression of thed isease to accelerated phase( AP)o rb last phase( BP)w hile minimizing anytherapy-related toxicity.Atpresent,the only proven curative therapyf or CMLi sa llogeneicb onem arrowt ransplant( BMT). The data with newertargeted therapiesdonot have adequatefollow-up to determinecurativepotential. This review will discuss pre-imatiniba nd imatinib-basedt herapiesu sedt ot reat CML, with theirrespectiveefficacyand toxicities. aBStract BACkgrOund:Chronic myeloid leukemia (CML)isahematopoieticstem cell cancer driven by theBCr-ABL fusionprotein that arises fromthe translocation of chromosomes9and 22.The disease begins with an indolentchronic phase(CP)thatcan last for3to5years.Ifuntreated, it progresses into accelerated phase(AP)and within ayear, blast phase (BP).Survival at this pointislessthan1year. during disease progression, mutationsand thePhiladelphia chromosome (Ph) appear(aprocess called clonal evolution). Theonlyknown curativetherapy forCML is allogeneic bone marrowtransplant(BMT). However, toxicity is formidable, with treatment-related mortalityreported in the30% range. Thus,effectivetherapy that maintainsthe patientwithCML in CP with minimaltoxicity is thegoal fortreatmentofmoderntherapies.Becausethe preeminent mutation drivingCML is BCr-ABL,therapies targetingBCr-ABL arethe logicalchoice fordisease-specifictherapy.BCr-ABL inhibitors, suchasimatinib,are proof that targetingspecificgenetic mutationsassociated with cancer yields ahighdegreeofefficacy with minimaltoxicity.
OBjeCTIve: This review will outlinethe evolution of therapyinCML.Preimatinib andimatinib-based treatmentstrategies,clinicalefficacy,and the mechanism of imatinib resistance will be discussed.
SuMMAry: Thediscovery of thePhand, subsequently,the identification of BCr-ABL revolutionizedthe treatmentofCML.Cytoreductivechemotherapy, suchasbusulfan and hydroxyurea,was amainstayoftherapy to control white blood cell (wBC)counts; however, it didnot modify the progressionofthe disease to AP andBP. Theoverall survival with CML ranges from45to58monthsinpatients treated with cytoreductivetherapy only.T reatment wasadvancedwiththe introduction of interferon (IFn ) immunotherapyinthe 1980s. In some studies, IFnp roducedacomplete hematologic response (CHr)inmore than 50%ofpatients;however,its nonspecific immunostimulatorymechanism alsoproduced severe flulike symptoms that limited tolerability.despite thesignificant toxicity,cost, andinconvenience of injectingIFn thrice weekly,mediansurvival ranged from60to89months. Allogeneic BMTisthe only knowncurativetherapy forCML;however,treatment-related mortalityfrominfection, bleeding, and graftversushostdisease, age, andthe availability of suitable donorslimits itswidespread use.
Imatinib functions by competingwithadenosine triphosphate (ATP)for bindingtothe BCr-ABL tyrosine kinase.Inthe absence of ATP, BCr-ABL is notabletoactivate downstream effector tyrosine kinase moleculesthat drivewBC proliferation.The International randomizedInterferonversus STI571 clinicaltrial wasthe firsttodocument theefficacy of imatinib as a first-line therapyfor patients in CP.Morethan90% of these patients hada CHr. Toxicities associated with this therapyare low. response in patients with advancedCML is less pronouncedthaninCPand is shorterlived, with less than 30%ofpatients achieving aCHr.For patients with CML in BP,the only viabletherapy is to attemptatemporaryreduction in disease burden with asalvage chemotherapyregimen, suchasvAC (etoposide, cytarabine,and carboplatin).The goal of this inductionchemotherapyisto induce asecondremission;thenthe patientmay be consideredfor allogeneic BMT.
Themaintoxicities seen with imatinib therapyare myelosuppression, edema, andmyalgia/arthralgia. In many cases,imatinib dosage can be briefly haltedorlowered whilethe toxicity is managed. Imatinib resistance maydevelopatany time andinevitablyleadstodiseaseprogression. 
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Themaintoxicities seen with imatinib therapyare myelosuppression, edema, andmyalgia/arthralgia. In many cases,imatinib dosage can be briefly haltedorlowered whilethe toxicity is managed. Imatinib resistance maydevelopatany time andinevitablyleadstodiseaseprogression. resistance is usually caused by mutationswithin BCr-ABL,decreasingthe affinity of imatinib binding. next-generation kinase inhibitorsare focused on theability to inhibit these mutated formsofBCr-ABL.
COnCLuSIOn:For themajorityofpatients with CML in CP,the standard of care is to maintain thepatientinCPwithimatinib therapy. Clinicaltrials have been extraordinarilysuccessful, with 5-year survival ratesgreater than 90%. Allogeneic BMTcontinuestobeanoption forthose whocannot tolerate imatinib or when CML progresses on imatinib therapy. Hydroxyurea, an S-phases pecifica gent,w as developeda sa saferalternativef or CMLtherapy.I tp rovidess hort-termc ontrol of WBCc ountsa nd spleen size.T oxicitiesa ssociated with this therapyi nclude nausea/vomiting, stomatitis,a nd rash.P atients progressed to AP andBP, with amedian survival of 58 months. Busulfan andh ydroxyurea didn ot eliminatet he Philadelphia chromosome positive (Ph+)c ells from theb onem arrowo rs ignificantlyslowthe progressionofthe diseasetoAPorBP.
The firstd rugt hatw as capableo fi ncreasingt he period of time during whicht he patientc ould remain in CP wasI FN∂ . IFN ∂ is an onspecific stimulanto ft he immune system that upregulates T-cell activity.I tp roduced ac omplete hematologic response (CHR)in40% to 80%ofpatientsand acompletecytogeneticresponse( CCR) in 6% to 10%ofpatients. This response translated into am edian survival of upwardso f8 9m onths. However,b ecause IFN ∂ is an onspecific immunostimulant, i t also produces flulikes ymptoms, causese xcessive fatigue, and, in some patients,causesd epression. In addition to theset oxicities,therapy required 3injections perw eekand wasexpensive. Manyp atientsd iscontinuedt herapyf or toxicity,c ost,o rc ompliance reasons. Am oderatei ncreasei ne fficacyw as observed whenI FN∂ wasc ombinedw ithl ow-dosec ytarabine; however, thecourseo fthe disease wasnodifferent from thatobservedin treatmentwithIFN∂ alone.
Bone Marrow Transplant
Allogeneic BMTi sap otentiallyc urative treatmentf or CML. Patient eligibility forthe procedure is predicated on identification of asuitabled onor,patient age, anddisease control. The patient must be youngerthan60years.Because themedian ageofdiagnosisf or CMLi s5 3y ears,m anyp atientsa re simply tooo ld at diagnosisf or BMTt ob eaviablet reatment option.I ft he transplantisperformed usingamatchedsibling as adonor,the chance forl ong-term disease-free survival ranges from 50%t o7 5%. 4 If thedonor is unrelated,the chance of long-termdisease-free survivalis40% to 50%, with an increased risk of earlymortality and graftversus host disease (GVHD). 5 The toxicities associated with this techniquea re formidable. Patientsa re at risk forb leedingc omplications andi nfectious complicationsd uringt he 2-to 3-week peritransplantp eriod whent heir blood counts arev eryl ow before bone marrow recovery (engraftment). Aftere ngraftment,p atientsa re at risk forGVHD, in whichthe donorbone marrow produces alloreactive T-cellsf romt he donor, whicha ttackt he recipient's tissues. Common organs affected by GVHD includet he skin,g astrointestinal (GI) tract, andl iver.G rade 3o rg rade 4G VHDa ssociated with thel iver or theG It ract is associated with mortality approaching1 00%.
Autologous BMTisdoneusing Ph negative cellsthatare recovered afterchemotherapyorafter ex vivo purging. 6 Unfortunately, thesep opulations containq uiescent CMLp rogenitors thatw ill ultimately produceaninevitable relapse. Thus,a utologous BMT is notafeasiblestrategy.
■■ Imatinib-based Therapy
Imatinib MechanismofAction
Imatinibm esylate,o riginallyc alled STI571,h as been commercially availablesince May2001. It worksbybinding to BCR-ABL andb lockingi ts function.B CR-ABL normally places phosphate groups on other proteins,w hich servet oa ctivatet hem. These proteins,i nt urn, activate downstream proteins,c reatinga n expandingc ascade of proteina ctivationt hatu ltimatelyr esults in uncontrolled growth.T oa ctivatethese downstream proteins, BCR-ABLrequiresadenosine triphosphate (ATP), whichdonates thephosphate group. ATPhas aspecial bindingsiteonBCR-ABL closetowherethe substrateproteinsbind (Figure 1, left panel) . 7 If theA TP bindingsiteisoccupied, then ATPcannotdonatethe phosphate andBCR-ABL cannolongeractivatedownstreamsignaling proteins thatpromote cell division (Figure 1, rightpanel) . Diseasep rogression is essentiallys topped by blockingt his1 ATPb inding site thath appenst os it at thei nitiatingn odeo fa 
ClinicalTrials: CP CML
Because many previousc ancert herapiesh aveb een disappointing, thee fficacydataf or imatinibare stunning. Theinitiallarge triali nvolvedp atientsw ho hadf ailed IFN ∂ treatment. 8 As a second-linet herapy,i matinibw as able to produceaC HR in 95%o fthe patients,resultinginn ormalization of blood counts. Furthermore, 66%o ft he patients showed al osso fP h+ cells or at leastar eduction of Ph+c ells in bone marrow biopsies. Cytogenetic andm olecular responsesa re showni nt he Table. First-line treatmento fnewly diagnosedpatientswithCML with imatinibp roducede venbetterresults. 9 This trial, knownasthe InternationalRandomizedInterferonv ersusS TI571 (IRIS) trial, generated as imilar number of CHRe vents; however, ag reater number of patients showed acomplete loss of Ph+cells (Table) . At thetimeofpublication,therewas no survival difference between thegroups; however, thetrial wasonly2years oldatthatpoint. Imatinibd id show some toxicity in this 2-year study-specifically, myelosuppression-ands omee levation in liverf unction tests. Patients whof ailedt herapyw erea blet oc ross over to the otherarm of thestudy.
At thet imeo fp ublication of the5 -yearf ollow-up data,6 5% of theIFN∂ grouphad switchedtoimatinibbecause of failureor intolerabletoxicities. 10 More than80% of thesepatientsachieved aC HR andm oret han5 0% achieved ac ytogenetic response (CR).Incomparison,69% of patients receivingfirst-lineimatinib remained on this therapyafter 5years.Only3%ofpatientswho discontinuedimatinibcrossed over to IFN ∂ therapy. The KaplanMeier analysis of imatinibresponses areshown in Figure 2 .
The percentage of patients whoa chievedaC HR begant o plateaua fter 12 months.M eanwhile,t he percentage of patients whoa chievedaC CR (completel osso fP h+ cells) continuedt o increase for30to36months. At the5-yearpoint,virtually 100% of patients hadachievedaCHR,90% hadachievedamajor CR, anda pproximately 85%had achieved aCCR.T he percentage of patients whor emainedf ree of disease progressiono ver this 5-year period was93%,and thenumberofpatientswho died from CMLwas 5%.These efficacydataare unprecedented forasingle agentinthe treatment of cancer.
The 5-year toxicity data were equallyc ompelling.T he most common toxicities reported were hematologicwitht he elevated transaminases.Remarkably, theset oxicitiesp resentedp rimarily within thefirst 2y ears andthenresolved.Inm ost chemotherapeutic programs,t oxicitiesc ontinue to worsen throughout the treatment.
Clinical Trials:AdvancedCML
The prognosisf or patients with CMLinAPand BP is inferior to thatseen in CP.I tispossiblet oo ffer BMTt opatientswho have progressed to AP;h owever,t he overalls urvivala nd treatmentrelated mortality ared emonstrablyw orse relative to patients in CP whou ndergot hisp rocedure.P atientsw ithC ML in AP do respond to imatinib; however, as thed isease burden increases, theefficacyo fimatinibd ecrease s. CHRwas achieved in 29%o f AP patients taking 400m gi matinibd aily( with 26%r eturning to CP)and in 41%o fAPp atientstaking600 mg imatinibdaily (with1 7% returningt oCP).
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Amajor CR wasa chievedin1 8% of AP patients on the4 00 mg imatinibd osea nd in 30%o fA P patients on the600 mg imatinibdose.
BP CMLh as ac linicalc oursea nalogous to acutel eukemia. Similarly, therapyf or this patientp opulationr everts to treating an acuteleukemia.One exampleisthe induction chemotherapy regimenV AC (etoposide,cytarabine, andcarboplatin). TheV AC regimenh ad an overallC Rr ateo f5 8% in 31 patients with median survival of 7m onths. 12 These chemotherapy regimens caninduceasecond temporaryCP. The goal with this reinduction chemotherapy is thatpatientscan revert to asecond CP long enough to be broughtt oB MT.I matiniba lsoh as been tested in patients with BP CML. 13 As in thep reviouss tudy,4 00 mg and 600mgd oses of imatinibwerecompared.ACHR wasachieved overall in 4% of the2treatment arms,withareturntoCPin19% overall (22% previouslyuntreated,15% treated). If tolerated,600 mg imatinibisthe preferreddose.
■■ Monitoring of Patients on Imatinib Therapy
Myelosuppression Increasedr isko fm yelosuppressioni st ypicallys eeni np atients whohaveahigherdegree of diseaseburdeninthe bone marrow, lowh emoglobin, al ongerp eriodo ft imef romt he initial diag-nosis, andcytopeniaswithp rior therapy. Sometimessupportive therapyusing growth factors, such as granulocyte-colony-stimulatingf actoro re rythropoietin,a re used; however, therea re no randomized trials demonstratings uperiority over observation alone. 14 Myelosuppressionc an be minimizedb ys toppingt he drug fora pproximately1monthu ntil patients'a bsoluten eutrophil countrecoversto>1,500ortheir plateletsrecover to >100,000.
14 If recovery is slow, theimatinibd oseisresumed at 300mgand slowly escalated to 400 mg over time.For patients with advanced CMLtaking600 mg imatinib, thestrategyissimilar.Therapy is held untilthe counts recover.However,the amount of diseasein theb onem arrowm ustb ec onsidered. If thel evel of diseasei s high,itisparamount to minimize theamountofdisease so normalhematopoiesis canberestored. Patients can be transfused or givenmyeloid growth factorstoamelioratethe condition.
Edema
Imatinibi nduces some degree of edemai np atients, oftenp eriorbital. 14 The risk of edemai si ncreased in females, in patients olderthan65years,and in patients with cardiacorrenal disease. Optionsi nclude decreasing thed o se to 300m ga nd instituting diureticstodecreasethe fluidburden. Forseverecases of edema, it maybeappropriate to instituteadrugholiday andrestart at a lowerdosewhenthe patientimproves.
OtherToxicities
Nauseaand vomitingcan be largelya voided by taking imatinib with food.M yalgia anda rthralgiam ay be treated with nonsteroidal anti-inflammatoryd rugs,w itht he caveat thatt he plateletc ount cannot be low. Rash is common.T he patientc an be rechallengedorthe imatinibdose lowered. Novartis will supply, on request, av erys pecifica lgorithm forr estartingt herapy at a lowerd oset ot ry to minimize recurrence of ther ash. Finally, imatinibinhibitscytochrome P450 3A4and thus hasn umerous drug interactions with otherd rugs usingt hisl iverm etabolic pathway.
■■ Imatinib Resistance
Acquired resistance refers to theability of CMLtodevelop resistancetoimatinibovertime. Disease progressiondespite imatinib is inevitablei np atientsw ho acquirethese mutations. The most common causeisthe mutation of BCR-ABLt oaf ormthatisn o longer sensitive to imatinib. This is them ost common form of resistance,a nd numerous mutationsc ausing resistance have been identified andc haracterized.A nother mechanism leading to resistance is gene amplification. Herethe number of BCR-ABL proteins produced exceedsthe ability of imatinibtoinhibit.
Primaryr esistancer eferst op atientsw ho do notr espond to imatinib. Again, mutationsw ithin BCR-ABLc an be thec ause. Additionally,o ther targets, such as SRC, mitogen-activated proteink inase, andt he NUP98/DDX10f usiong enep roduct, have been implicated;h owever,these targetsare much less common. Imatinibr esistancel eads to diseasep rogression andh as necessitated thed evelopment of newerd rugs capableo fi nhibiting mutated formso fBCR-ABL.These newerinhibitorswill be covered in thenextarticle in this supplement.
■■ Conclusions
CMLtherapyhas progressed from nonspecificcytoreductive chemotherapiesw ithl imited efficacyt oah ighlyt argeted inhibitor with extraordinarye fficacy. More than9 0% of imatinib-treated patients in theI RISt rial remain alivea nd progressionf ree 5 yearsout.T oxicitiesare lowand occurprimarily within thefirst 2years of treatment. Resistance is amajor problembecause it can developa ta ny time andl eadt od isease progression. Data from theIRIStrial suggestthatacquired resistance is notcommon, at leastwithin the5-yearspanofthe trial.Nevertheless, newinhibitors arerequiredtodeal with this problem. Inhibitors of this type arecurrentlyinclinicaltrialsand show greatpromise.
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